Literature DB >> 6385610

Treatment of idiopathic nephrotic syndrome with levamisole.

P Niaudet, R Drachman, M F Gagnadoux, M Broyer.   

Abstract

Thirty children with frequently relapsing idiopathic nephrotic syndrome (INS) were treated with levamisole (2.5 mg/kg BW) twice a week for a mean period of 9.9 months. A beneficial effect was observed in 16 children in whom corticosteroids could be significantly decreased without relapse. Levamisole was ineffective in 14 patients. There was no difference between the two groups in the duration of INS, the number of relapses and the duration of treatment with levamisole. The mean age at onset of INS was higher in the group of patients where levamisole was effective (5.8 years versus 2.8 years). In 7 patients who responded to levamisole neutrophils decreased below 4 X 10(9)/l. Transient granulocytopenia was observed in 3. It is concluded that levamisole may be effective in frequently relapsing INS with minimal side effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385610     DOI: 10.1111/j.1651-2227.1984.tb09988.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  11 in total

1.  Treatment of partially corticosteroid-sensitive nephrotic syndrome with levamisole.

Authors:  M L Mancini; S Rinaldi; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

2.  Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  A R Kreeftmeijer-Vegter; T P C Dorlo; M P Gruppen; A de Boer; P J de Vries
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

3.  Side effects of levamisole in children with nephrosis.

Authors:  J B Palcoux; P Niaudet; P Goumy
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

4.  Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  Ahmet Taner Elmas; Yılmaz Tabel; Ozlem Nalbantoğlu Elmas
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

Review 5.  Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.

Authors:  Asha Moudgil; Arvind Bagga; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

6.  Long-term effects of levamisole treatment in childhood nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Béla Iványi; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

Review 7.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

8.  Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome.

Authors:  Olivia Boyer; Janelle K Moulder; Laure Grandin; Michael J G Somers
Journal:  Pediatr Nephrol       Date:  2008-01-16       Impact factor: 3.714

Review 9.  Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?

Authors:  J C Davin; M P Merkus
Journal:  Pediatr Nephrol       Date:  2004-09-17       Impact factor: 3.714

10.  Clinical efficacy of levamisole in the treatment of primary nephrosis in children.

Authors:  J G Mongeau; P O Robitaille; F Roy
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.